-
Mashup Score: 11ClinicalTrials.gov - 14 day(s) ago
Hide glossary Study record managers: ref er to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 4
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile Expanded approval brings this personalized CAR T cell therapy to more patients with relapsed or refractory multiple myeloma earlier in their treatment journey as a one-time infusion offering meaningful treatment-free intervals when responding to therapy Abecma is now approved in the U.S., Japan, Switzerland and the EU for earlier use for triple-class exposed relapsed and/or refractory multiple myeloma, underscoring BMS’ commitment to delivering Abecma globally, with consistently high manufacturing success rates and continuous increases in capacity Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) have announced that on April 4, 2024, the U.S. Food and Drug Administration (FDA) approved Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with
Source: news.bms.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 4
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile Expanded approval brings this personalized CAR T cell therapy to more patients with relapsed or refractory multiple myeloma earlier in their treatment journey as a one-time infusion offering meaningful treatment-free intervals when responding to therapy Abecma is now approved in the U.S., Japan, Switzerland and the EU for earlier use for triple-class exposed relapsed and/or refractory multiple myeloma, underscoring BMS’ commitment to delivering Abecma globally, with consistently high manufacturing success rates and continuous increases in capacity Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) have announced that on April 4, 2024, the U.S. Food and Drug Administration (FDA) approved Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with
Source: news.bms.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 13
One of the organs most frequently impacted by amyloidosis is the kidney. Dr. Jeffrey Zonder from the Karmanos Cancer Institute provides a brief summary of am…
Source: www.youtube.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 0Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial - 6 month(s) ago
Ixazomib maintenance prolongs PFS and represents an additional option for post-transplant maintenance therapy in patients with newly diagnosed multiple myeloma.
Source: www.thelancet.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 0Live updates: New Orleans-area tornado - 1 year(s) ago
A confirmed tornado moved through New Orleans around 4 p.m., according to the National Weather Service. Follow our live updates.
Source: CNNCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 2ASH22 - 1 year(s) ago
Download the program for ASH22. Easily access event sessions, speakers, exhibitors, and organizer messages. Download the native app to personalize your schedule, take notes, share contacts, and more. Try the interactive web version More features available for iOS and Android …
Source: ativsoftware.comCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 0AL Amyloidosis | CCO Free CE/CME Event - 1 year(s) ago
Virtual Simulcast In-Person Free CME Credits Join us in New Orleans or via simulcast for a 2-hour live, CME-certified satellite symposium on diagnosing and managing amyloid light-chain (AL) amyloidosis. You will gain insights from a panel of experts on diagnostic…
Source: pages.mycea.comCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 1
On October 25, 2022, the Food and Drug Administration granted accelerated approval to teclistamab-cqyv (Tecvayli, Janssen Biotech, Inc.), the first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adult patients with relapsed or refractory multiple myeloma who have receiv
Categories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 0Potential fabrication in research images threatens key theory of Alzheimer’s disease - 2 year(s) ago
A neuroscience sleuth challenges data showing one toxic form of amyloid protein is a cause of brain condition
Source: www.science.orgCategories: Hematologists1, Latest HeadlinesTweet
Great day today at the 3rd #midwestcellular conference! I got to talk about high risk #myeloma. I’d say HRMM was my arch-nemesis if it weren’t for Stage IV AL #amyloidosis. That’s why @karmanoscancer has the AFFIRM-AL trial open. https://t.co/t2EgIEnXAQ